...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Onkologie >Antitumor effect of everolimus in a patient with type 3 gastric Neuroendocrine Tumor
【24h】

Antitumor effect of everolimus in a patient with type 3 gastric Neuroendocrine Tumor

机译：依维莫司对3型胃神经内分泌肿瘤患者的抗肿瘤作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Gastric neuroendocrine tumors (NET) are rare and are classified into 3 types: type 1 and 2 (characterized by hypergastrinemia), and type 3 (characterized by normal gastrin). Surgery is the standard procedure, and systemic treatment is reserved for unresectable disease. Currently, targeted therapies are being evaluated in NET. The activity of everolimus, an mTOR inhibitor, has been shown in pancreatic NET but not reported in type 3 gastric carcinoid tumors. Case Report: Here we report a case of a patient who, after multiple lines of systemic therapy, had a prolonged disease control of nearly 1 year, significant clinical benefit, and minor tumor shrinkage with oral everolimus 10 mg continuously. Conclusion: There is no effective treatment for type 3 gastric carcinoid tumors. The frequency of mTOR expression in these tumors is not known, but the case reported here suggests that inhibition of this pathway may play an important role.
机译：背景：胃神经内分泌肿瘤（NET）很少见，分为3型：1型和2型（以高胃泌素血症为特征）和3型（以正常胃泌素为特征）。外科手术是标准程序，全身治疗只适用于不可切除的疾病。当前，NET中正在评估目标疗法。 mTOR抑制剂依维莫司的活性已在胰腺NET中显示，但在3型胃类癌肿瘤中未见报道。病例报告：在此我们报道了一名患者，该患者经过多系全身治疗后，疾病控制时间延长了将近1年，临床效果显着，并且口服依维莫司10 mg持续口服可使肿瘤缩小。结论：目前尚无有效的治疗3型胃类癌的方法。这些肿瘤中mTOR表达的频率尚不清楚，但此处报道的病例表明该途径的抑制可能起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号